Skip to content

A Sham Controlled Study of the Effects of Ultrasonic Shockwaves as a Treatment for Chronic Pelvic Pain

Low Intensity Extracorporeal Shockwave Therapy Against Chronic Pelvic Pain: a Randomized and Sham Controled Study

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02042651
Acronym
CPPESWT
Enrollment
0
Registered
2014-01-23
Start date
2014-02-28
Completion date
2016-02-29
Last updated
2015-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pelvic Pain

Keywords

ESWT, Chronic pelvic pain, randomized, sham controlled

Brief summary

Introduction: Chronic pelvic pain with unknown pathology is a condition that affects both men and women. the condition is defined as pelvic pain lasting for a minimum of 6 months without any known etiology eg. cancer, infection or inherent anatomical abnormalities. Low intensity extracorporeal shockwave therapy (LIESWT) enables the practitioner to deliver a small amount of energy approximately 5 cm under the skin of the patient without damaging the skin. This have been shown to increase blood flow and accelerate healing which could also be beneficial in chronic pelvic pain patients.The purpose of this study is to investigate the effects of LIESWT on chronic pelvic pain. Methods: All patients will be treated at the Birthe Bonde clinic, in Copenhagen, Denmark. The investigators anticipate to include 100 chronic pelvic pain patients in the study. included patients will be randomized into two groups: active treatment or sham treatment. All patients will be required to provide a urine sample and a semen sample prior to final inclusion. Samples will be analyzed for microbial growth. Furthermore, patients will undergo a digital rectal exploration and finally all patients is required to provide an informed consent in order to be included in the study. A Storz Doulith SD1 T-Top (CE1275) will be used to generate shockwaves. Patients will receive the treatment once a week until their symptoms have seized or for a maximum of 6 times. Each treatment consists of 3000 shockwaves applied to the perineum with a energy density of 0.25-0.40 millijoule(mJ)/mm2 and a frequency of 3 hz. Participants will fill out a questionnaire one week before the treatment, one week, four weeks, and twelve weeks after the last treatment. Possible gains from this study: The investigators hope to provide further evidence for this treatment and consequently be able to offer the treatment as an alternative to the very limited array of treatments existing for this group of patients today. Ethics, funding, and publication: The study is performed in compliance with the Helsinki declaration. External funding have been applied for but not yet received. Participants will be informed of sources of external funding. The result of the study will be published as soon as possible, preferably in a peer-reviewed international journal.

Interventions

DEVICELow intensity extracorporeal shockwave therapy

Shockwaves will be applied to the perineum a total of 6 times once per week. The energy level applied will range between 0.25 and 0.40 mJ/mm2 with a frequency of 3 Hz for a total of 3000 shockwaves per treatment session

DEVICESham low intensity extracorporeal shockwave therapy

Shockwaves will be applied to the perineum a total of 6 times once per week. The shockwaves will be blocked by a medium on the handheld applicator.

Sponsors

Herlev Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* pelvic pain with a duration of more than 6 months * be able to read and understand the study information

Exclusion criteria

* known etiology for pelvic pain eg. cancer, infection, inherent abnormalities. * diagnosed with hemophilia * receiving anti thrombotic therapy other than hearth magnyl * diagnosed with thrombocytosis * active cancer * treated with IV glucocorticoids within the last 6 months * disease in the rectal area * abnormal digital rectal exploration * bacteriospermia

Design outcomes

Primary

MeasureTime frameDescription
Change in NIH-Chronic Prostatitis Symptom IndexChange from baseline to twelve weeks after final treatmentA questionnaire designed to provide symptom scores for patients with chronic prostatitis. The index provides scores on pain, urinary symptoms, and quality of life.

Secondary

MeasureTime frameDescription
Change in The International Index of Erectile Function 5Change from baseline to twelve weeks after final treatmentQuestionnaire designed to evaluate erectile capabilities. The questionnaire provides a score between 5 and 25.
Change in The International prostate symptom scoreChange from baseline to twelve weeks after final treatmentA questionnaire designed to provide information on lower urinary tract symptoms and their impact on quality of life. scores range from 0 to 35.
Global satisfaction scoreTwelve weeks after final treatmentOne question designed to estimate treatment satisfaction on a four point Likert scale.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026